PHARMACYTE BIOTECH, INC. Debt Conversion, Converted Instrument, Amount
PHARMACYTE BIOTECH, INC. (PMCB) reported Debt Conversion, Converted Instrument, Amount of $4.78 million for the 12-month period ending 2014-04-30, per its 10-K filed 2016-07-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2016-07-29
- PHARMACYTE BIOTECH, INC. debt conversion, converted instrument, amount for fiscal 2014 was $4.78M, a 3231.34% increase from fiscal 2013.
- PHARMACYTE BIOTECH, INC. debt conversion, converted instrument, amount for fiscal 2013 was $143.60K.
| Period end | Debt Conversion, Converted Instrument, Amount 1 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|
| 2014-04-30 | $4.78M 10-K · filed 2016-07-29 | |
| 2013-05-31 | $4.47M 10-Q · filed 2013-09-16 | |
| 2013-04-30 | $143.60K 10-K/A · filed 2016-01-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |